Protalix BioTherapeutics Profile

USD 0.0009  0.20%

Sale by Yossi Maimon of 40300 shares of Protalix BioTherapeutics

Protalix BioTherapeutics insider trading alert for sale of common stock by Yossi Maimon, VP Chief Financial Officer, on July 11, 2018. This event was filed by Protalix Biotherapeutics with SEC on 2009-10-19. Statement of changes in beneficial ownership - SEC Form 4. Yossi Maimon is currently serves as cfo, vice president treasurer, secretary of Protalix BioTherapeutics [view details]   

Protalix BioTherapeutics Summary

Protalix BioTherapeutics (PLX) is traded on BATS Exchange in USA. It is located in ISRAEL and employs 190 people. Protalix BioTherapeutics is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Micro-Cap' category with total capitalization of 65.36 M. Protalix BioTherapeutics runs under Healthcare sector within Pharmaceutical Products industry. This company has 145.57 M outstanding shares of which 2.43 M shares are at this time shorted by investors with about 4.43 days to cover shorted positions. PROTALIX BIOTHERA has about 41.32 M in cash with (10.98 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.28.
Check Protalix BioTherapeutics Probability Of Bankruptcy

Ownership Allocation (%)

Target Price Odds Analysis

Odds Below 0.4499HorizonTargetOdds Above 0.4499
64.18%30 days 0.45 35.75%
Based on normal probability distribution, the odds of Protalix BioTherapeutics to move above current price in 30 days from now is about 35.75% (This Protalix BioTherapeutics probability density function shows the probability of Protalix BioTherapeutics Stock to fall within a particular range of prices over 30 days) .

Top Holders

Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Davenport Co Llc 1Common Shares20 K9 K
Highbridge Capital Management LlcDebt19.6 M17.4 M
Opaleye Management IncCommon Shares3.3 M1.8 M
View Protalix BioTherapeutics Diagnostics

Selected Protalix BioTherapeutics Income Statement Over Time

Net Income    Revenues    

Key Fundamentals

Protalix BioTherapeutics Against Markets

Current Ratings

Protalix BioTherapeutics 30 Days Performance Scores
Risk Adjusted
Performance Score (0 to 100)
Chance of
Financial Distress (0 to 100%)
Equity ratings for Protalix BioTherapeutics are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. Protalix BioTherapeutics, Inc. was founded in 1993 and is based in Karmiel, Israel. Protalix BioTherapeutics operates under Biotechnology classification in USA and traded on American Stock Exchange. It employs 190 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Protalix BioTherapeutics SEC Filings
Protalix BioTherapeutics SEC Filings
Security & Exchange Commission EDGAR ReportsView All
NameProtalix BioTherapeutics
CEO and President and DirectorMoshe ManorView All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
Healthcare, Biotechnology
InstrumentUSA Stock View All
RegionNorth America
Business Address2 Snunit Street
Foreign Associate  Israel
ExchangeBATS Exchange
CIK Number0001006281
IndustryPharmaceutical Products
Phone972 4 988 9488
CurrencyUSD - US Dollar

Current Sentiment - PLX

Protalix BioTherapeutics Investor Sentiment
Greater number of Macroaxis users are at this time bullish on Protalix BioTherapeutics. What is your perspective on investing in Protalix BioTherapeutics? Are you bullish or bearish?
98% Bullish
2% Bearish

Protalix BioTherapeutics Corporate Directors

Roger Kornberg Independent Director, Ph.D
Amos BarShalev Independent Director, MBA
Aharon Schwartz Independent Director, Ph.D
Additionally take a look at Your Equity Center. Please also try Price Ceiling Movement module to calculate and plot price ceiling movement for different equity instruments.